Which has higher earnings & valuation, GERN or ALKS?

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $183.88M 5.31 -$83.50M -$0.11 N/A Alkermes $1.48B 5.49 $241.66M $0.38 127.18

Is GERN or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Geron's net margin of -34.17%. Alkermes' return on equity of 4.15% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Geron -34.17% -24.48% -10.30% Alkermes 3.96% 4.15% 2.19%

Does the media favor GERN or ALKS?

In the previous week, Alkermes had 1 more articles in the media than Geron. MarketBeat recorded 5 mentions for Alkermes and 4 mentions for Geron. Alkermes' average media sentiment score of 1.02 beat Geron's score of 0.13 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Alkermes 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RCUS or GERN more profitable?

Geron has a net margin of -34.17% compared to Arcus Biosciences' net margin of -393.16%. Geron's return on equity of -24.48% beat Arcus Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Arcus Biosciences -393.16% -89.54% -45.61% Geron -34.17% -24.48% -10.30%

Does the media favor RCUS or GERN?

In the previous week, Arcus Biosciences had 2 more articles in the media than Geron. MarketBeat recorded 6 mentions for Arcus Biosciences and 4 mentions for Geron. Arcus Biosciences' average media sentiment score of 0.71 beat Geron's score of 0.13 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, ABCL or GERN?

Geron has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbCellera Biologics $75.13M 46.20 -$146.41M -$0.54 N/A Geron $183.88M 5.31 -$83.50M -$0.11 N/A

Is ABCL or GERN more profitable?

Geron has a net margin of -34.17% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets AbCellera Biologics -248.83% -17.49% -12.36% Geron -34.17% -24.48% -10.30%

Does the media refer more to ABCL or GERN?

In the previous week, AbCellera Biologics had 1 more articles in the media than Geron. MarketBeat recorded 5 mentions for AbCellera Biologics and 4 mentions for Geron. AbCellera Biologics' average media sentiment score of 0.97 beat Geron's score of 0.13 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor IOVA or GERN?

In the previous week, Iovance Biotherapeutics had 8 more articles in the media than Geron. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 4 mentions for Geron. Iovance Biotherapeutics' average media sentiment score of 0.54 beat Geron's score of 0.13 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 1 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer GERN or GMTX?

Geron currently has a consensus target price of $4.00, indicating a potential upside of 163.16%. Given Geron's stronger consensus rating and higher probable upside, analysts plainly believe Geron is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer GERN or GMTX?

In the previous week, Geron had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 4 mentions for Geron and 1 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.75 beat Geron's score of 0.13 indicating that Gemini Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Gemini Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Geron (GERN) Competitors

$1.52 -0.03 (-1.94%)

As of 08/21/2026 04:00 PM Eastern

Compare

GERN vs. ALKS, RCUS, ABCL, IOVA, and GMTX

Should you buy Geron stock or one of its competitors? Geron's main competitors and comparable companies include Alkermes (ALKS), Arcus Biosciences (RCUS), AbCellera Biologics (ABCL), Iovance Biotherapeutics (IOVA), and Gemini Therapeutics (GMTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Geron compare to Alkermes?

Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

73.7% of Geron shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Alkermes has a net margin of 3.96% compared to Geron's net margin of -34.17%. Alkermes' return on equity of 4.15% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Alkermes	3.96%	4.15%	2.19%

Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	5.31	-$83.50M	-$0.11	N/A
Alkermes	$1.48B	5.49	$241.66M	$0.38	127.18

Geron has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

In the previous week, Alkermes had 1 more articles in the media than Geron. MarketBeat recorded 5 mentions for Alkermes and 4 mentions for Geron. Alkermes' average media sentiment score of 1.02 beat Geron's score of 0.13 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alkermes	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Geron currently has a consensus target price of $4.00, suggesting a potential upside of 163.16%. Alkermes has a consensus target price of $54.56, suggesting a potential upside of 12.90%. Given Geron's higher possible upside, equities analysts clearly believe Geron is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Summary

Alkermes beats Geron on 15 of the 17 factors compared between the two stocks.

How does Geron compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Geron has a net margin of -34.17% compared to Arcus Biosciences' net margin of -393.16%. Geron's return on equity of -24.48% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Geron	-34.17%	-24.48%	-10.30%

Geron has lower revenue, but higher earnings than Arcus Biosciences. Geron is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	15.54	-$353M	-$3.90	N/A
Geron	$183.88M	5.31	-$83.50M	-$0.11	N/A

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 7.6% of Arcus Biosciences shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Arcus Biosciences currently has a consensus price target of $37.80, indicating a potential upside of 25.41%. Geron has a consensus price target of $4.00, indicating a potential upside of 163.16%. Given Geron's higher probable upside, analysts plainly believe Geron is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Arcus Biosciences had 2 more articles in the media than Geron. MarketBeat recorded 6 mentions for Arcus Biosciences and 4 mentions for Geron. Arcus Biosciences' average media sentiment score of 0.71 beat Geron's score of 0.13 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Arcus Biosciences has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Summary

Arcus Biosciences beats Geron on 10 of the 16 factors compared between the two stocks.

How does Geron compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

AbCellera Biologics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Geron has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Geron has a net margin of -34.17% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Geron	-34.17%	-24.48%	-10.30%

Geron has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	46.20	-$146.41M	-$0.54	N/A
Geron	$183.88M	5.31	-$83.50M	-$0.11	N/A

AbCellera Biologics presently has a consensus target price of $12.83, suggesting a potential upside of 13.37%. Geron has a consensus target price of $4.00, suggesting a potential upside of 163.16%. Given Geron's higher probable upside, analysts plainly believe Geron is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, AbCellera Biologics had 1 more articles in the media than Geron. MarketBeat recorded 5 mentions for AbCellera Biologics and 4 mentions for Geron. AbCellera Biologics' average media sentiment score of 0.97 beat Geron's score of 0.13 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

AbCellera Biologics beats Geron on 9 of the 17 factors compared between the two stocks.

How does Geron compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Iovance Biotherapeutics currently has a consensus target price of $8.75, suggesting a potential upside of 5.55%. Geron has a consensus target price of $4.00, suggesting a potential upside of 163.16%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Iovance Biotherapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

In the previous week, Iovance Biotherapeutics had 8 more articles in the media than Geron. MarketBeat recorded 12 mentions for Iovance Biotherapeutics and 4 mentions for Geron. Iovance Biotherapeutics' average media sentiment score of 0.54 beat Geron's score of 0.13 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Geron has a net margin of -34.17% compared to Iovance Biotherapeutics' net margin of -89.11%. Geron's return on equity of -24.48% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Geron	-34.17%	-24.48%	-10.30%

Geron has lower revenue, but higher earnings than Iovance Biotherapeutics. Geron is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	14.25	-$390.98M	-$0.73	N/A
Geron	$183.88M	5.31	-$83.50M	-$0.11	N/A

Summary

Iovance Biotherapeutics beats Geron on 10 of the 16 factors compared between the two stocks.

How does Geron compare to Gemini Therapeutics?

Geron (NASDAQ:GERN) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

73.7% of Geron shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Geron has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

Gemini Therapeutics has a net margin of 0.00% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Gemini Therapeutics has lower revenue, but higher earnings than Geron. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	5.31	-$83.50M	-$0.11	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Geron currently has a consensus target price of $4.00, indicating a potential upside of 163.16%. Given Geron's stronger consensus rating and higher probable upside, analysts plainly believe Geron is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Geron had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 4 mentions for Geron and 1 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.75 beat Geron's score of 0.13 indicating that Gemini Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Geron	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Gemini Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Geron beats Gemini Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GERN vs. The Competition

Export

Metric	Geron	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$976.56M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-13.82	11.62	272.60	24.25
Price / Sales	5.31	1,334.62	623.83	101.53
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	4.47	16.80	13.05	6.20
Net Income	-$83.50M	-$12.50M	$3.47B	$348.59M
7 Day Performance	3.40%	3.29%	2.09%	0.08%
1 Month Performance	4.83%	8.23%	6.64%	3.88%
1 Year Performance	4.11%	55.05%	25.02%	16.98%

Geron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GERN Geron	1.7481 of 5 stars	$1.52 -1.9%	$4.00 +163.2%	+4.1%	$976.56M	$183.88M	N/A	70
ALKS Alkermes	3.1837 of 5 stars	$48.02 -4.3%	$54.56 +13.6%	+62.5%	$8.42B	$1.48B	126.37	2,050	Positive News
RCUS Arcus Biosciences	3.0077 of 5 stars	$29.61 -2.4%	$37.80 +27.7%	+186.8%	$3.86B	$117M	N/A	500
ABCL AbCellera Biologics	2.293 of 5 stars	$11.57 -3.7%	$12.83 +10.9%	+157.9%	$3.68B	$66.17M	N/A	500
IOVA Iovance Biotherapeutics	1.6892 of 5 stars	$8.99 +12.5%	$8.75 -2.7%	+208.2%	$3.62B	$263.50M	N/A	500	News Coverage Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GERN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Geron (GERN) Competitors

GERN vs. ALKS, RCUS, ABCL, IOVA, and GMTX

How does Geron compare to Alkermes?

Summary

How does Geron compare to Arcus Biosciences?

Summary

How does Geron compare to AbCellera Biologics?

Summary

How does Geron compare to Iovance Biotherapeutics?

Summary

How does Geron compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GERN vs. The Competition

Geron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Geron (GERN) Competitors

GERN vs. ALKS, RCUS, ABCL, IOVA, and GMTX

How does Geron compare to Alkermes?

Do institutionals and insiders hold more shares of GERN or ALKS?

Is GERN or ALKS more profitable?

Which has higher earnings & valuation, GERN or ALKS?

Which has more risk & volatility, GERN or ALKS?

Does the media favor GERN or ALKS?

Do analysts prefer GERN or ALKS?

Summary

How does Geron compare to Arcus Biosciences?

Is RCUS or GERN more profitable?

Which has better valuation & earnings, RCUS or GERN?

Do institutionals and insiders have more ownership in RCUS or GERN?

Do analysts prefer RCUS or GERN?

Does the media favor RCUS or GERN?

Which has more risk & volatility, RCUS or GERN?

Summary

How does Geron compare to AbCellera Biologics?

Which has more risk and volatility, ABCL or GERN?

Is ABCL or GERN more profitable?

Which has preferable valuation & earnings, ABCL or GERN?

Do analysts rate ABCL or GERN?

Do institutionals & insiders believe in ABCL or GERN?

Does the media refer more to ABCL or GERN?

Summary

How does Geron compare to Iovance Biotherapeutics?

Do analysts prefer IOVA or GERN?

Which has more volatility and risk, IOVA or GERN?

Does the media favor IOVA or GERN?

Do insiders and institutionals hold more shares of IOVA or GERN?

Is IOVA or GERN more profitable?

Which has stronger valuation & earnings, IOVA or GERN?

Summary

How does Geron compare to Gemini Therapeutics?

Do institutionals and insiders believe in GERN or GMTX?

Which has more volatility & risk, GERN or GMTX?

Is GERN or GMTX more profitable?

Which has stronger earnings & valuation, GERN or GMTX?

Do analysts prefer GERN or GMTX?

Does the media prefer GERN or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GERN vs. The Competition

Geron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools